About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Baltimore | 23,476 Studies Near You | Clareo Health

Clinical Trials LocationsBaltimore

Clinical Trials in Baltimore

Discover 23,476 clinical trials near Baltimore, Maryland. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 19041-19060 of 23,476 trials

COMPLETEDPhase 1< 1 mile

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

NCT00207155

The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer

Metastatic Colorectal Cancer

Eli Lilly and Company110 participantsStarted Dec 2003

Duarte, California, United States • Tampa, Florida, United States • Baltimore, Maryland, United States +11 more locations

COMPLETEDPhase 3< 1 mile

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

NCT02032888

A study of the efficacy and safety of the combination of daclatasvir and sofosbuvir in the treatment of hepatitis C virus and HIV coinfection.

Bristol-Myers Squibb238 participantsStarted Feb 2014

Birmingham, Alabama, United States • Beverly Hills, California, United States • Long Beach, California, United States +34 more locations

Find Trials by Condition in Baltimore

Breast Cancerin Baltimore Lung Cancerin Baltimore Prostate Cancerin Baltimore Colorectal Cancerin Baltimore Melanomain Baltimore Leukemiain Baltimore Lymphomain Baltimore Pancreatic Cancerin Baltimore Ovarian Cancerin Baltimore Brain Cancerin Baltimore

Data from ClinicalTrials.govTerms

UNKNOWNPhase 1< 1 mile

A Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers

NCT02587442

This is a Phase 1, non-randomized, sequential-cohort, dose escalation, open-label study designed to evaluate the safety and tolerability of RadProtect® in healthy volunteers. This study is to be conducted at two clinical centers and in conformity with Good Clinical Practice (GCP).

Acute Radiation Syndrome

Original BioMedicals Co. Ltd.27 participantsStarted Oct 2015

Baltimore, Maryland, United States

COMPLETED< 1 mile

Impact of Impaired Cerebral Autoregulation on Postoperative Delirium in Elderly Patients Undergoing Spine Surgery

NCT01574950

Delirium (confusion) after surgery is common and associated with a longer hospitl stay and increased hopsital cost. There is very little information available about how often delirium occurs and the complications associated with it. Elderly patients are at high risk for delirium after surgery. This research is being done to measure how often delirium after spine surgery occurs and to see if there are ways to predict if delirium will develop. The results from this study will provide important information on a possible mechanism and predictor of delirium.

Johns Hopkins University99 participantsStarted Mar 2012

Baltimore, Maryland, United States

COMPLETEDPhase 3< 1 mile

Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder

NCT01370733

This study is designed to evaluate the safety and efficacy of synchronized transcranial magnetic stimulation (sTMS) using the NeoSync EEG Synchronized TMS device (NEST) in subjects with Major Depressive Disorder. This is a multicenter study in which subjects will be randomized to receive treatment 5 days per week for 6 weeks. Subjects who complete 6 weeks of double-blind treatment may be eligible to receive up to four weeks of open label sTMS therapy or antidepressant medications during the follow-up phase of the study. Follow-up evaluation visits will be conducted during those four weeks, with the frequency of the visits determined by the treatment choice during that timeframe.

Major Depressive Disorder

Wave Neuroscience202 participantsStarted May 2012

Los Angeles, California, United States • San Diego, California, United States • Torrance, California, United States +15 more locations

COMPLETEDPhase 2< 1 mile

Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients

NCT01125189

To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid virologic response rates at least 35% greater than those with placebo.

Hepatitis C Virus

Bristol-Myers Squibb558 participantsStarted Jul 2010

Montgomery, Alabama, United States • La Jolla, California, United States • Los Angeles, California, United States +61 more locations

COMPLETEDPhase 2< 1 mile

Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)

NCT00874770

The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.

Hepatitis C Infection

Bristol-Myers Squibb74 participantsStarted Jun 2009

Montgomery, Alabama, United States • Aurora, Colorado, United States • New Haven, Connecticut, United States +11 more locations

COMPLETEDPhase 134 miles

A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer

NCT01121575

Lung cancer tumors become resistant to the first generation epidermal growth factor receptor (EGFR) inhibitors erlotinib or gefitinib by changing and increasing the activity of two cell signaling pathways: the cMET pathway and the EGFR pathway. Both resistance mechanisms can occur at the same time, in the same patient and even in the same tumor. This study combines a second generation EGFR inhibitor and a cMET inhibitor to block both these pathways in order to overcome resistance and treat this disease.

Non Small Cell Lung Cancer

Pfizer70 participantsStarted Aug 2010

Aurora, Colorado, United States • Aurora, Colorado, United States • Aurora, Colorado, United States +7 more locations

TERMINATEDPhase 234 miles

Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer

NCT01856322

Background: \- Some types of inflammation may increase the risk of cancers in the intestinal track. Because of this possibility, anti-inflammatory drugs may be able to prevent tumor growth and spread. One such drug, sulindac, may be helpful to study. Researchers want to see if people who are having surgery to remove intestinal tumors from advanced colorectal cancer will benefit from sulindac. It will be tested against a placebo. Objectives: \- To see if sulindac can improve treatment outcomes in people who are having surgery for advanced colorectal cancer. Eligibility: \- Individuals at least 18 years of age who are having surgery for advanced colorectal cancer. Design: * Participants will be screened with a physical exam and medical history. Blood samples will be collected. Imaging studies and heart and lung function tests may also be given. * Participants will be separated into two groups. One group will take sulindac. The other will take a placebo. * Participants will take sulindac or placebo twice daily from about 2 to 3 weeks before the scheduled surgery. Seven days before the surgery, they will stop taking the pills. * Participants will have surgery to remove their tumors. The surgery will also remove affected organ tissue. * Participants will start to take the pills again once they have recovered from surgery. They will continue taking the sulindac or placebo twice a day for 3 years, or for as long as the tumors do not return.

Colorectal CancerLiver MetastasisColorectal Adenocarcinoma

National Cancer Institute (NCI)3 participantsStarted Apr 2013

Bethesda, Maryland, United States

TERMINATEDPhase 234 miles

Vandetanib to Treat Advanced Kidney Cancer

NCT01372813

Background: * One way tumors are able to grow is by forming new blood vessels that supply it with nutrients and oxygen. * Vandetanib (ZD6474) is an experimental drug that blocks certain proteins on the surface of tumor and blood vessel cells that are involved with the formation of new blood vessels. * Blocking these proteins may prevent the tumor cells or blood vessels from continuing to grow. Objectives: * To determine whether vandetanib can cause tumors to shrink or stabilize in patients with advanced kidney cancer. * To determine how vandetanib may work in people with kidney cancer and to develop tests that may be helpful in studying kidney cancer. Eligibility: -Patients 18 years of age or older with advanced clear cell kidney cancer whose disease has worsened after treatment with one or more of the following drugs: sunitinib, sorafenib, interleukin-2 and temsirolimus; or patients who have had to stop treatment with these drugs due to unacceptable side effects; or patients who are unable to receive standard treatment. Design: * Patients take a vandetanib pill once a day in 28-day cycles. * Patients are followed in the clinic every 2 weeks during the first month of treatment and then every 4 weeks for a physical examination, blood and urine tests, electrocardiogram and a review of any drug side effects. * Patients have imaging scans (computed tomography (CT) or magnetic resonance imaging (MRI)) about every 8 weeks to monitor tumor growth. MRI scans are also done to look at tumor blood flow when treatment begins, 24 hours after the first dose of treatment, and again about 4 and 8 weeks after starting treatment * Optional tumor biopsies (surgical removal of a sample of tumor tissue) may be done before starting vandetanib treatment and after 4 weeks of treatment to look for drug effects on the tumor.

Advanced Clear Cell Renal Carcinoma

National Cancer Institute (NCI)3 participantsStarted Dec 2007

Bethesda, Maryland, United States

COMPLETED36 miles

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00450281

RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for lung cancer and may help the study of cancer in the future. PURPOSE: This clinical trial is studying carcinogens in lung tissue from smokers (closed to entry as of 7/15/07) and non-smokers with newly diagnosed stage I, stage II, or stage III non-small cell lung cancer.

SWOG Cancer Research Network981 participantsStarted Oct 2005

Anchorage, Alaska, United States • Tucson, Arizona, United States • Fort Smith, Arkansas, United States +402 more locations

COMPLETED36 miles

Evaluation of Multisensor Data in Heart Failure Patients With Implanted Devices

NCT01128166

The goal of the MultiSENSE study is to collect chronic information from multiple sensors in an implanted device for evaluation in heart failure patients.

Boston Scientific Corporation975 participantsStarted Jun 2010

Anchorage, Alaska, United States • Gilbert, Arizona, United States • Little Rock, Arizona, United States +96 more locations

COMPLETEDNA41 miles

A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach

NCT02230657

The purpose of this study is to identify differences in satisfaction, pain and length of stay between patients undergoing hip replacement who are discharged from the hospital on the day of surgery compared to patients who stay one night in the hospital.

Osteoarthritis of the Hip

Rothman Institute Orthopaedics

Philadelphia, Pennsylvania, United States • Alexandria, Virginia, United States

COMPLETEDPhase 153 miles

Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

NCT00207077

The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).

Eli Lilly and Company33 participantsStarted Aug 2005

Newark, Delaware, United States

COMPLETEDNA109 miles

A Trial of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone in Patients With ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary PCI

NCT01149044

This is an international, randomized, controlled, parallel group study in which patients with ST-Segment Elevation Myocardial Infarction (STEMI) will be allocated to one of the following: Manual aspiration thrombectomy with Percutaneous Coronary Intervention (PCI) or PCI alone.

Acute Coronary SyndromeST Elevation Myocardial InfarctionPercutaneous Coronary Intervention

Population Health Research Institute10,732 participantsStarted Aug 2010

Bakersfield, California, United States • Atlanta, Georgia, United States • Albuquerque, New Mexico, United States +84 more locations

COMPLETEDPhase 2169 miles

A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces

NCT00162110

This is a Phase II open-label trial evaluating the efficacy, and safety of Erbitux in patients with mucinous gastrointestinal adenocarcinoma involving the peritoneal surface.

Mucinous Gastrointestinal Adenocarcinoma

Eli Lilly and Company40 participantsStarted Nov 2004

New York, New York, United States • Cincinnati, Ohio, United States

COMPLETEDPhase 4169 miles

A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization

NCT00465101

To gain clinical experience with the GreenLight HPS System, a system designed to vaporize and coagulate tissue in the treatment of benign prostatic hyperplasia to reduce lower urinary tract symptoms.

Benign Prostatic Hyperplasia

American Medical Systems150 participantsStarted May 2007

Los Angeles, California, United States • Middlebury, Connecticut, United States • Roswell, Georgia, United States +6 more locations

COMPLETED169 miles

Prostate Biomarker Study

NCT00574899

Radical Prostatectomy (removal of the prostate) or radiation therapy provide excellent outcomes for patients with localized (confined to one area) disease, yet there is still no effective treatment once the disease has spread beyond the prostate gland. Typically, a serum PSA test is done to diagnose prostate cancer. Following diagnosis, a prostate biopsy and other tests help to classify the patient's disease according to the likelihood of a recurrence. However, these assessments are imperfect. There is a need to identify and evaluate prostate biomarkers that will provide exact information regarding the likelihood of a recurrence (prediction) of prostate cancer.

Prostate Cancer

Memorial Sloan Kettering Cancer Center32 participantsStarted May 2007

Los Angeles, California, United States • New York, New York, United States

TERMINATEDPhase 1181 miles

A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome

NCT00282399

The purpose of this study was to determine which of the doses of decitabine maximizes genomic demethylation in patients with Myelodysplastic Syndrome (MDS).

Myelodysplastic Syndrome

Eisai Inc.41 participantsStarted Oct 2006

Tucson, Arizona, United States • Tampa, Florida, United States • The Bronx, New York, United States

TERMINATEDPhase 11498 miles

This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors

NCT00932126

This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients. The study will assess the compound's safety, the blood levels of PF-03758309 during the treatment and the effect of the compound on the tumor cells.

Advanced Solid Tumors

Pfizer35 participantsStarted Sep 2009

Santa Monica, California, United States • Aurora, Colorado, United States • East Melbourne, Victoria, Australia

PreviousPage 953 of 1174Next

Diabetes

in Baltimore

Heart Diseasein Baltimore